Jacob Borodovsky, PhD
Senior Research Scientist, Center for Technology and Behavioral Health and the Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth
Jacob Borodovsky, PhD is a Senior Research Scientist and Epidemiologist at the Center for Technology and Behavioral Health and the Department of Biomedical Data Science at Dartmouth’s Geisel School of Medicine. His research program centers on two big questions: Why do people use psychoactive substances, and how can science and policy change these behaviors to improve public health? Jake’s work integrates measurement science, novel data collection methods, advanced analytic approaches, and computational modeling to advance the study of substance use. He is developing the field of Cannabis Regulatory Science by creating standardized ways to measure cannabis exposure, examining how marketing and policy influence consumer behavior, and designing tools that regulators can use to evaluate compliance and guide decision-making.
In addition to cannabis, Jake applies large-scale national datasets to investigate topics such as adolescent technology use, prescription medication patterns, and connections between substance use and mental health. He also studies ways to strengthen the evidence base for treatments for opioid use disorder in young people, with a focus on improving access and adherence. His goal is to generate research that both advances science and directly informs policy, regulation, and clinical practice. His work has shaped policy discussions in the U.S. and internationally, and he has been interviewed by The New York Times, Time Magazine, and NPR.
Outside of work, Jake practices Brazilian Jiu Jitsu, hikes, reads, and spends time with his Chihuahua, Roxy.
Selected Publications
- Schuman-Olivier Z, Weiss RD, Hoeppner BB, Borodovsky J, Albanese MJ. Emerging adult age status predicts poor buprenorphine treatment retention. J Subst Abuse Treat. 2014 Sep;47(3):202-12. doi: 10.1016/j.jsat.2014.04.006. PMID: 24953168; PMCID: PMC4180514.
- Schuman-Olivier Z, Connery H, Griffin ML, Wyatt SA, Wartenberg AA, Borodovsky J, Renner JA Jr, Weiss RD. Clinician beliefs and attitudes about buprenorphine/naloxone diversion. Am J Addict. 2013 Nov-Dec;22(6):574-80. doi: 10.1111/j.1521-0391.2013.12024.x. PMID: 24131165; PMCID: PMC3801272.
- Schuman-Olivier Z, Hoeppner BB, Weiss RD, Borodovsky J, Shaffer HJ, Albanese MJ. Benzodiazepine use during buprenorphine treatment for opioid dependence: Clinical and safety outcomes. Drug Alcohol Depend. 2013 Oct 1;132(3):580-6. doi: 10.1016/j.drugalcdep.2013.04.006. PMID: 23688843; PMCID: PMC3916951.